Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients

QR Code

Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients

Imatinib mesylate (IM) is a BCR-ABL targeted tyrosine kinase inhibitor drug used for frontline therapy in patients with chronic myeloid leukemia (CML). IM is highly effective and is considered the standard of care in CML management. Even though IM has become the gold standard frontline treatment...

Full description

Bibliographic Details
Main Author:	Elias, Marjanu Hikmah
Format:	Thesis
Language:	English
Published:	2015
Subjects:	R Medicine
Online Access:	http://eprints.usm.my/40418/ http://eprints.usm.my/40418/1/Dr._Marjanu_Hikmah_Elias_PhD-24_pages.pdf

Similar Items

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Elias, Marjanu Hikmah, et al.
Published: (2012)

Detection of PDGFRA mutations at exons 12 and 18 among chronic myeloid leukemia patients treated with imatinib mesylate
by: Razali, Ruzi Hamimi
Published: (2015)

Molecular basis of primary and secondary resistance to imatinib mesylate
by: Abdul Aziz, Baba
Published: (2012)

Genetic determinants excluding GBCR::ABL mutations of imatinib mesylate therapy response among chronic myeloid leukaemia patients in Malaysia
by: Ismail, Siti Mariam
Published: (2023)

Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
by: Mardziah M,, et al.
Published: (2019)

Influence of tert gene expression, telomerase activity and telomere length in relation to imatinib mesylate resistance in Malaysian chronic myeloid leukaemia patients
by: Shamshudin, Wati @ Hayati Mohd
Published: (2020)

Determination of gene copy number status in tert and terc among chronic myeloid leukaemia patients resist ant and responsive to imatinib mesylate treatment
by: Asrari, Zaidatul Shakila Mohamad
Published: (2014)

Imatinab mesylate treatment in Chronic Myeloid Leukemia (CML)- understanding the fundamental pharmacokinetic and pharmacogenetic mechanisms for variation in response
by: Ankathil, Ravindran
Published: (2016)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
by: Chen, Li-Chia, et al.
Published: (2014)

Application of high resolution melting (HRM) analysis in detection of PDGFRA gene mutations among chronic myeloid leukemia patients treated with imanitib mesylate
by: Rashid, Nur Sabrina Abd
Published: (2020)

Influence of ORM1, PXR, CAR, CYP3A4 and CYP3A5 gene polymorphisms in mediating susceptibility risk to chronic myeloid leukaemia and response to imatinib mesylate therapy
by: Maddin, Najlaa
Published: (2017)

Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
by: Liong, Tan Ka
Published: (2013)

C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice
by: Knight, B., et al.
Published: (2008)

Imbalanced expression of polycistronic miRNA in acute myeloid leukemia
by: Kotaki, Ryutaro, et al.
Published: (2017)

Exploration Of Real Time PCR As A New Diagnostic Method Of Fragile X Syndrome
by: Elias, Marjanu Hikmah
Published: (2010)

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
by: Ley, T., et al.
Published: (2013)

Clinical evaluation and proteomic profiles of acute myeloid leukemia patients, Saudi Arabia
by: Almaiman, Amer Abdulrahman
Published: (2015)

Effects of epigallocatechin-3-gallate (EGCG) on cell cycle distribution and DNA integrity of K562 cells, a human chronic myeloid leukemia
by: Elda Surhaida Latif,, et al.
Published: (2020)

Proteomics profiling and genomics computational analysis of acute myeloid leukemia / Md. Mirazul Islam
by: Md. Mirazul, Islam
Published: (2017)

Concomitant t(8;21) and trisomy 4 in a patient with Acute Myeloid Leukemia (AML)
by: Phan CL,, et al.
Published: (2010)

Analysis of Madm, a novel adaptor protein that associates with Myeloid Leukemia Factor 1
by: Lim, Raelene
Published: (2003)

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells
by: Alharbi, Raed A., et al.
Published: (2017)

ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia
by: Abdullah, Maha, et al.
Published: (2017)

Targeted RNAi of the mitogen-activated protein kinase pathway genes in acute myeloid leukemia cells
by: Mohd Hafiz, M.R., et al.
Published: (2013)

Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
by: Abdullah, Maha, et al.
Published: (2009)

Subtractive hybridization identifies stem cell-associated genes in an acute myeloid leukemia with poor prognosis
by: Ngiow, Shin Foong, et al.
Published: (2016)

Eccentricity of Acute Myeloid Leukemia with NPM1 and FLT3-ITD mutation: a case report
by: Nur Zainura Mohamad,, et al.
Published: (2022)

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
by: Young, Christine S., et al.
Published: (2017)

Cytotoxic Effects of Betulinic Acid and its Derivatives on Human Myeloid Leukemia (Hl-60) Cell Line
by: Faujan, Nur Hana
Published: (2008)

Chronic consumption of fructose dysregulates genes related to glucose and lipid metabolism in prostate tissue
by: Norhazlina Abdul Wahab,, et al.
Published: (2018)

Using chromosome engineering on a natural isolate of the fission yeast, Schizosaccharomyces pombe, to investigate the epigenetic inheritance of the kinetochore
by: Barbosa, Anne Caroline
Published: (2018)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Epigenetic modifiers and minerals as tools to diversify secondary metabolite production in fungi
by: Siti Hajar Sadiran,, et al.
Published: (2022)

Epigenetic modifiers and minerals as tools to diversify secondary metabolite production in fungi
by: Siti Hajar Sadiran,, et al.
Published: (2022)

Antileukemic Effect of Tualang Honey on Acute and Chronic Leukemia Cell Lines
by: Nik Man, Nik Muhd Khuzaimi, et al.
Published: (2015)

Gene Expression, Biochemical And Functional Analysis Of Stromal Interaction Molecule 1 (Stim1) Silencing In Acute Myeloid Leukemia Cell Lines
by: Algariri, Eman Salem Saeed
Published: (2022)

The cytotoxicity effect of ant-444 in human chronic myeloid leukaemia cells (K 562)
by: Khalid, Nor Bahijah, et al.
Published: (2013)

Cytotoxic effect of betulinic acid and betulinic acid acetate isolated from Melaleuca cajuput on human myeloid leukemia (HL-60) cell line
by: Faujan, Nur Hana, et al.
Published: (2010)

Reviewing the epigenetics of schizophrenia
by: Cromby, John, et al.
Published: (2016)

Survival analysis in acute myeloid leukemia: A retrospective cohort study and simulation study of small events per independent variable / Law Kian Boon
by: Law , Kian Boon
Published: (2017)